Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$0.76 ▼ +0.00
(-0.54%)
MKT CAP: $136.2M • VOL: 2.03M
52W L $1 52W H $7
ROARABLE / RQD
D • 46/100
PIOTROSKI
2 / 9
CMPX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$72.8M | -$56.6M | -$50.4M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$66.5M | -$49.4M | -$42.5M |
| EBITDA (Normalized) | -$72.8M | -$56.6M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$49.1M | -$44.9M | -$40.6M |
| Capital Expenditures (CapEx) | $25.0K | $44.0K | — |
| Free Cash Flow (FCF) | -$49.2M | -$44.9M | -$40.6M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -34.6% | -45.0% | — |
| Cash & Short-Term Equivalents | $30.6M | $43.5M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $196.8M | $125.2M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CMPX.